RecruitingNCT05040178

An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and Pediatrics

A Non-Interventional Post-Authorization Safety Study (PASS) of Carbaglu® for the Treatment of Hyperammonemia Due to Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA) in Adult and Pediatric Patient Populations

Sponsor

RECORDATI GROUP

Enrollment

20 participants

Start Date

Jun 30, 2022

Study Type

OBSERVATIONAL

Conditions

Propionic Acidemia Methylmalonic Acidemia Hyperammonemia

Summary

To obtain short-term and long-term clinical safety information, in pediatric and adult patients with PA and MMA treated with Carbaglu®.

Eligibility

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Carglumic Acid for people with hyperammonemia, methylmalonic acidemia, and other related conditions. The study is currently recruiting participants at 5 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.